Clinical Trial Update: Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a phase 1/2 study evaluating a low-dose superparamagnetic iron oxide agent for sentinel lymph node localization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• superparamagnetic iron oxide contrast agent (superparamagnetic iron oxide nanoparticles)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Breast Cancer, Sentinel Lymph Node | Phase 1, Phase 2 | Status: COMPLETED